companyprofile
Actions
Middle East Pharmaceutical Industries Co.
- Main Market
- Pharma, Biotech & Life Science
Stats Overview
-
Prev. Close 132.60
-
Open 132.80
-
High 133.40
-
Low 130.00
-
No. of Trades 1,314
-
Avg. Trade size* 53
-
Volume Traded 70,242
-
Value Traded (SAR) 9,241,494.20
Performance
- *Average Trade Size = Cumulative / # of Trades
- **52 Week Price Change = (Current Price - Price year ago) / Price year ago x 100
- Historical prices & volume traded data are adjusted to account for all corporate actions.
- MO: Market Order
Trade Updates
Last Trade
Best Bid
Best Offer
52 WEEK
PERFORMANCE
Compare Selected
Select a Maximum of 5 Companies
LoginPortletPopupv2
Actions
AddtoWatchlistv2
Actions
AnnouncmentandCorporateAction
Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Announcements
Corporate Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Dividends
| Announced Date | Eligibility Date | Distribution Date | Distribution Way | Dividend Amount |
|---|---|---|---|---|
| 30/07/2024 | 01/09/2024 | 15/09/2024 | Account Transfer | 0.75 |
CompanyProfilev2Financials
Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Financials
- FINANCIAL INFORMATION
- FINANCIAL STATEMENTS AND REPORTS
- Annually
- Quarterly
| Balance Sheet | 2023-12-31 | |||
|---|---|---|---|---|
| Total Assets |
444,898.75
|
- | - | - |
| Total Liabilities |
138,499.23
|
- | - | - |
| Total Shareholders Equity (After Deducting the Minority Equity) |
306,399.52
|
- | - | - |
| Total Liabilities and Shareholders Equity |
444,898.75
|
- | - | - |
| Statement of Income | 2023-12-31 | |||
| Total Revenue (Sales/Operating) |
338,439.7
|
- | - | - |
| Net Profit (Loss) before Zakat and Tax |
71,438.23
|
- | - | - |
| Zakat and Income Tax |
-5,610.88
|
- | - | - |
| Net Profit (Loss) after Zakat and Tax |
65,827.35
|
- | - | - |
| Total Comprehensive Income |
62,125.89
|
- | - | - |
| Profit (Loss) per Share |
3.29
|
- | - | - |
| Cash Flows | 2023-12-31 | |||
| Net Cash From Operating Activities |
92,659.34
|
- | - | - |
| Net Cash From Investing Activities |
-30,833.35
|
- | - | - |
| Net Cash From Financing Activities |
-70,509.64
|
- | - | - |
| Cash and Cash Equivalents, Beginning of the Period |
23,790.84
|
- | - | - |
| Cash and Cash Equivalents, End of the Period |
15,107.19
|
- | - | - |
| All Figures in | Thousands | |||
| All Currency In | SAR | |||
| Last Update Date | 2024-03-25 |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
| Balance Sheet | ||||
|---|---|---|---|---|
| Total Assets | ||||
| Total Liabilities | ||||
| Total Shareholders Equity (After Deducting the Minority Equity) | ||||
| Total Liabilities and Shareholders Equity | ||||
| Statement of Income | ||||
| Total Revenue (Sales/Operating) | ||||
| Net Profit (Loss) before Zakat and Tax | ||||
| Zakat and Income Tax | ||||
| Net Profit (Loss) after Zakat and Tax | ||||
| Total Comprehensive Income | ||||
| Profit (Loss) per Share | ||||
| Cash Flows | ||||
| Net Cash From Operating Activities | ||||
| Net Cash From Investing Activities | ||||
| Net Cash From Financing Activities | ||||
| Cash and Cash Equivalents, Beginning of the Period | ||||
| Cash and Cash Equivalents, End of the Period | ||||
| All Figures in | ||||
| All Currency In | ||||
| Last Update Date |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Company Profile
Company overview
Avalon Pharma develops, manufactures, markets and distributes a wide range of generic medicines and pharmaceuticals in the Kingdom of Saudi Arabia and abroad through a diversified, high-quality product portfolio covering several therapeutic categories.
Company History
Middle East Pharmaceutical Industries Co. was established as a limited liability company under Commercial Registration number (1010150538) issued in Riyadh on 02/04/1419H (corresponding to 26/07/1998G). In 2022G, the company was converted into a Joint Stock on 13/09/1443H (corresponding to 14/04/2022G).
Company Bylaws
Equity Profile
- Authorized Capital (SAR) 200,000,000
- Issued Shares 20,000,000
- Paid Capital (SAR) 200,000,000
- Par Value/Share 10
- Paid Up Value/Share 10
Last Update :2024-02-26
Investment limits
There are no investment limits on the company's shares as per the amended Rules for Qualified Foreign Financial Institutions Investment in Listed Securities and Instructions for the Foreign Strategic Investors Ownership in Listed Companies based on Company's bylaw and the issued Instructions by related regulators and supervisory authorities.
- Company Details
- BOARD OF DIRECTORS AND SENIOR EXECUTIVES INFORMATION
Investor Relations
Contact Name:
Investor Relations Department
Company Address:
Second Industrial City, Riyadh P.B. 3800 Riyadh 14331
Contact Details:
Telephone:
2653948 11 966+
Fax
: 2654723 11 966+
Email
: investor.relations@avalon.com.sa
Company Website:
| Name Of Subsidiary | Percentage Of Property | Main Business | Location Of Operation | Country Of Operation |
|---|---|---|---|---|
| Avalon Pharma UK Holding Ltd | 100.00% | Manufacturing of medicine, medical creams, non-medical creams, and ointments | United Kingdom | United Kingdom |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of these disclosures, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of these disclosures, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.